Neuigkeiten

CryoCath to Present at BMO Healthcare Conference

Montreal, July 30, 2008 - CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products to treat cardiac arrhythmias, today announced that Jan Keltjens, President and CEO of CryoCath, will present a corporate update at the BMO Focus on Healthcare Conference. The Company’s presentation will take place Wednesday, August 6th at 8:30 a.m. (ET) in Room 2 at the Millennium Broadway Hotel in New York City.

Interested parties may access a live webcast of Mr. Keltjens’ presentation by visiting the company’s website at www.cryocath.com.

About Medtronic CryoCath

CryoCath – www.cryocath.com – is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.

For further information, please contact:

Ross Marshall
Phone: 416 815 0700 ext. 238
E-mail: rmarshall@equicomgroup.com